I agree these would be interesting acquisition tar
Post# of 148321
(Total Views: 301)
Posted On: 04/16/2019 9:29:35 PM
I agree these would be interesting acquisition targets, though I personally don't think they would do the DNA density test unless it somehow benefits cancer also (unless they do not intend to license HIV).
Dr. Pestell, Dr. Massimo Cristofanilli, Massimo and Dr. Xuanmao Jiao share the CTC patent, so I could see some shares being issued for CYDY to acquire complete rights from the other two.
I also think Menarini-Silicon Biosystems CELLSEARCH Circulating Tumor Cell (CTC) Test would make sense. I believe they presented with Dr. Pestell and Dr. Cristofanilli at AACR a few weeks ago on the CCR5/CTC presentation:
"One presentation will cover research from Northwestern University that used the FDA-cleared CELLSEARCH Circulating Tumor Cell (CTC) Test to conduct CTC testing on metastatic breast cancer (MBC) patients.* The study was co-authored by Massimo Cristofanilli, M.D., F.A.C.P., Associate Director of Translational Research at Robert H. Lurie Cancer Center, Northwestern University. It will report on a significant correlation between high levels of co-expression of CCR5 and HER2 in CTCs. CCR5 has been associated with cancer stem cells and believed to drive metastatic process. The researchers suggest that CCR5 may contribute to more aggressive phenotype by upregulating HER2 expression. It is the first evidence of identifying CCR5 expression in CTCs as a potential new marker for MBC with potential therapeutic implications."
“This is an exciting study, as it provides evidence of CCR5 being a potential therapeutic target for breast cancer,” said Dr. Cristofanilli. “This observation is the basis of an upcoming clinical trial incorporating detection CCR5/CTC expression and in which we will target CCR5 with a specific antibody in the hopes of preventing metastasis and prolong disease control in patients with TNBC.”
Menarini-Silicon Biosystems CELLSEARCH AACR PR:
http://www.siliconbiosystems.com/press-releas...ast-cancer
Shared CTC Patent
http://www.freepatentsonline.com/y2018/0303830.html
Dr. Pestell, Dr. Massimo Cristofanilli, Massimo and Dr. Xuanmao Jiao share the CTC patent, so I could see some shares being issued for CYDY to acquire complete rights from the other two.
I also think Menarini-Silicon Biosystems CELLSEARCH Circulating Tumor Cell (CTC) Test would make sense. I believe they presented with Dr. Pestell and Dr. Cristofanilli at AACR a few weeks ago on the CCR5/CTC presentation:
"One presentation will cover research from Northwestern University that used the FDA-cleared CELLSEARCH Circulating Tumor Cell (CTC) Test to conduct CTC testing on metastatic breast cancer (MBC) patients.* The study was co-authored by Massimo Cristofanilli, M.D., F.A.C.P., Associate Director of Translational Research at Robert H. Lurie Cancer Center, Northwestern University. It will report on a significant correlation between high levels of co-expression of CCR5 and HER2 in CTCs. CCR5 has been associated with cancer stem cells and believed to drive metastatic process. The researchers suggest that CCR5 may contribute to more aggressive phenotype by upregulating HER2 expression. It is the first evidence of identifying CCR5 expression in CTCs as a potential new marker for MBC with potential therapeutic implications."
“This is an exciting study, as it provides evidence of CCR5 being a potential therapeutic target for breast cancer,” said Dr. Cristofanilli. “This observation is the basis of an upcoming clinical trial incorporating detection CCR5/CTC expression and in which we will target CCR5 with a specific antibody in the hopes of preventing metastasis and prolong disease control in patients with TNBC.”
Menarini-Silicon Biosystems CELLSEARCH AACR PR:
http://www.siliconbiosystems.com/press-releas...ast-cancer
Shared CTC Patent
http://www.freepatentsonline.com/y2018/0303830.html
(0)
(0)CytoDyn Inc (CYDY) Stock Research Links
Please do your own due diligence. All my posts and comments are not to be considered investment advice.
Scroll down for more posts ▼